Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6UQNW)

• Drug Name: F4co vaccine Drug Info
• Synonyms: F4co vaccine (AIDS/HIV infection)

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Phase 2	[1] , [2]

• Cross-matching ID: TTD Drug ID: DM6UQNW

Molecule-Related Drug Atlas

Drug(s) Targeting Human immunodeficiency virus Reverse transcriptase (HIV RT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[4]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[5]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[6]
Tenofovir	DM1IS6U	Human immunodeficiency virus infection	1C62	Approved	[4]
Lamivudine	DMI347A	Chronic HBV infection	1E51.0Z	Approved	[7]
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[8]
Delavirdine	DM3NF5G	Human immunodeficiency virus infection	1C62	Approved	[7]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[7]
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[9]
Etravirine	DMGV8QU	Human immunodeficiency virus-1 infection	1C62	Approved	[10]

Drug(s) Targeting Human immunodeficiency virus Capsid p24 (HIV p24)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GS-6207	DMW7TZV	Human immunodeficiency virus infection	1C62	Phase 2/3	[11]
Vacc-4x	DMDAKZW	Human immunodeficiency virus-1 infection	1C62	Phase 2	[12]

Drug(s) Targeting Human immunodeficiency virus Negative factor (HIV nef)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LIPO-5	DMWY0V1	Human immunodeficiency virus infection	1C62	Phase 2	[13]
Ad35-GRIN	DM4L28K	Human immunodeficiency virus infection	1C62	Phase 1/2	[14]
Ad35-GRIN/ENV	DMG82ZA	Human immunodeficiency virus infection	1C62	Phase 1	[14]
GSK-732461	DMJ0ZB6	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[15]
MYRISTIC ACID	DMYX0BL	Discovery agent	N.A.	Investigative	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Capsid p24 (HIV p24)	TTTWS2G	POL_HV1B1	Not Available	[3]
Human immunodeficiency virus Matrix p17 (HIV MA)	TTI3NXG	POL_HV1B1	Not Available	[3]
Human immunodeficiency virus Negative factor (HIV nef)	TT4NXYM	NEF_HV1A2	Not Available	[3]
Human immunodeficiency virus Reverse transcriptase (HIV RT)	TT84ETX	POL_HV1B1	Not Available	[3]

References

• [1] ClinicalTrials.gov (NCT01218113) Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naive HIV-1 Infected Persons. U.S. National Institutes of Health.
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027409)
• [3] EP patent application no. 2621528, Vaccine.
• [4] Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
• [5] HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
• [6] A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
• [9] Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
• [10] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [11] Clinical pipeline report, company report or official report of Gilead Sciences.
• [12] Clinical pipeline report, company report or official report of Bionor Pharma.
• [13] HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9.
• [14] A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
• [15] Preventive technologies, research toward a cure, and immune-based and gene therapies. HIV Treatment Bulletin. 30 June 2013.
• [16] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.